EllenRx®Allergy/Immunology

Rinvoq denied by insurance? What insurers ask for and how to appeal

upadacitinib · Sources reviewed Nov 10, 2026 · Sources below

Used for
9 conditions (see above)
How it's given
By mouth
Prior authorization usually required?
Varies by plan

What does my insurer usually ask for before approving Rinvoq?

  • For arthritis or gut conditions: tried a TNF blockerRinvoq is approved for these conditions after a TNF blocker (like Humira) did not work or was not tolerated, so plans ask for that history. If a TNF blocker is not right for you, plans may accept another treatment for UC or Crohn's.
  • For eczema: tried another body-wide treatment firstFor eczema, Rinvoq is meant for people whose eczema was not controlled by other medicines that work through the whole body, such as a biologic shot.
  • Prescribed by or with a specialistPlans want a specialist for your condition, such as a joint, skin, allergy, or stomach doctor, to prescribe or advise.
  • Not combined with biologics or strong immune drugsRinvoq should not be used with other biologics, other JAK drugs, or strong immune-lowering drugs, and plans will not pay for that combination.
  • TB test before startingRinvoq can wake up a hidden tuberculosis infection, so the label and plans call for a TB test before your first dose.

Based on published policies from several large commercial insurers and the FDA label (see Sources). Medicare, Medicaid and other plans may use different rules. Your plan's rules may differ.

Why was Rinvoq denied, and what can I do?

  1. Decode your denial letter: Ellen explains the reason in plain words.
  2. Check your denial type and your rights (Medicare or Medicaid if that's your coverage).
  3. Build your appeal, with the step-by-step appeal guide.
Decode my Rinvoq denial

How can I lower the cost of Rinvoq?

If you have Medicare or Medicaid, check each program's terms before you apply.

How does Rinvoq compare?

Safety information

From FDA-approved prescribing information for Rinvoq (JAK Inhibitor).

Boxed warning

Major adverse cardiovascular events (MACE), malignancy, thrombosis (DVT/PE), serious infections, increased mortality vs. TNF inhibitors

Do not use if

  • Active serious infections
  • Clinically significant hypersensitivity to upadacitinib

Key warnings

  • FDA restricts to patients who have failed TNF inhibitors
  • Screen for TB, viral hepatitis before starting
  • Monitor lymphocytes, neutrophils, hemoglobin, lipids, liver enzymes
  • Increased risk of herpes zoster. Consider vaccination before starting
  • Avoid in patients >65, current/former smokers, or those with CV risk factors unless no alternatives

This is not a complete list. See the full Rinvoq prescribing information or ask your pharmacist for complete safety information.

For clinicians: Rinvoq prior authorization card (printable).

Sources: FDA prescribing information for Rinvoq (DailyMed) and these insurers' published policies: Aetna (Policy Rinvoq SGM 3173-A P2026a, page dated June 14, 2026), Cigna (Effective 06/01/2026). Checked 2026-11-10. Sources reviewed Nov 10, 2026.

Not medical advice. This page is for educational and informational purposes only. It does not replace professional medical judgment. Always consult your prescribing physician or pharmacist before starting, stopping, or changing any medication. Ellen does not provide medical advice, diagnose conditions, or recommend treatments. Coverage rules vary by plan and change often; confirm with your plan's current policy.